Video

Dr. Grisham on Frontline Treatment for Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses frontline treatment options for patients with low-grade serous ovarian cancer.

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses frontline treatment options for patients with low-grade serous ovarian cancer.

This is a very rare subset of ovarian cancer, Grisham says, with approximately 1300 cases every year in the United States. The low incidence of this disease makes it difficult for investigators to develop effective, personalized therapy. In the upfront setting, there is a GOG study (NRGGY019) that will open soon to investigate the role of chemotherapy in this setting. In the trial, newly diagnosed patients will be randomized to receive either chemotherapy followed by hormonal therapy with letrozole or hormonal therapy with letrozole alone—both following initial surgical resection.

An unanswered question in this space is whether chemotherapy, which has demonstrated meager activity in the frontline setting, can be replaced by hormonal therapy for patients with advanced-stage disease. Grisham says that in the absence of any prospective data, she still recommends upfront chemotherapy for these patients; however, she feels that results from his study will help identify the roles of chemotherapy and hormonal therapy in the upfront setting.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity